<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079365</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000355400</org_study_id>
    <secondary_id>USFPG-6034</secondary_id>
    <nct_id>NCT00079365</nct_id>
  </id_info>
  <brief_title>Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas</brief_title>
  <official_title>A Randomized Trial Comparing 5-Fluorouracil, External Beam Radiation, and Gemcitabine With or Without P Radiopharmaceutical Therapy As A First Line Therapy in Patients With Locally/Regionally Advanced Non-Resectable Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Radiation&#xD;
      therapy uses high-energy x-rays to damage tumor cells. Fluorouracil may make the tumor cells&#xD;
      more sensitive to radiation therapy. Brachytherapy uses radioactive material, such as&#xD;
      phosphorus P32, placed directly into or near a tumor to kill tumor cells. Combining&#xD;
      chemotherapy and external-beam radiation therapy with brachytherapy may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying fluorouracil, gemcitabine, external-beam&#xD;
      radiation therapy, and brachytherapy using phosphorus P32 to see how well they work compared&#xD;
      to fluorouracil, gemcitabine, and external-beam radiation therapy in treating patients with&#xD;
      locally or regionally advanced unresectable adenocarcinoma of the pancreas (pancreatic&#xD;
      cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the survival of patients with locally or regionally advanced unresectable&#xD;
           adenocarcinoma of the pancreas treated with fluorouracil, external beam radiotherapy,&#xD;
           and gemcitabine with vs without brachytherapy with phosphorus P32 suspension.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare time to disease progression, tumor response rate, and physical performance in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety and tolerability of these regimens in this patient population.&#xD;
&#xD;
        -  Compare duration of response and time to treatment failure in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive phosphorus P32 suspension percutaneously under CT guidance on&#xD;
           day 0 and at months 1, 2, 6, 7, and 8. Patients receive fluorouracil IV continuously on&#xD;
           days 1-5 of weeks 1-6. Patients concurrently undergo external beam radiotherapy 5 days a&#xD;
           week on weeks 1-6. At the completion of radiotherapy, patients receive gemcitabine IV&#xD;
           over 30 minutes once weekly for 7 weeks. After a 1-week rest, patients then receive&#xD;
           gemcitabine IV over 30 minutes once weekly for 3 weeks. Treatment repeats every 28 days.&#xD;
&#xD;
        -  Arm II: Patients receive fluorouracil and gemcitabine and undergo external beam&#xD;
           radiotherapy as in arm I.&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this&#xD;
      study within 24-30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2001</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>phosphorus P32</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
               -  Locally or regionally advanced disease&#xD;
&#xD;
          -  Unresectable disease defined by the following:&#xD;
&#xD;
               -  Invasion into a major vascular structure determined preoperatively by a CT scan,&#xD;
                  angiogram, or CT portogram or intraoperatively by surgeon&#xD;
&#xD;
               -  Severe comorbidities precluding operation, such as congestive heart failure,&#xD;
                  coronary artery disease, or chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Bidimensionally measurable disease by CT scan&#xD;
&#xD;
          -  No recurrent disease&#xD;
&#xD;
          -  No previously resected pancreatic cancer&#xD;
&#xD;
          -  No tumors of the pancreas not ductal in origin (e.g., islet cell tumors, lymphoma, or&#xD;
             sarcoma)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count: ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively resected basal cell&#xD;
             carcinoma of the skin, carcinoma in situ of the cervix or breast, or early stage&#xD;
             prostate cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for pancreatic adenocarcinoma&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior chromic phosphate P32 suspension (Phosphocol®)&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy for pancreatic adenocarcinoma&#xD;
&#xD;
          -  At least 4 weeks since prior investigational anti-tumoral agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Rosemurgy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USF Physician's Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

